CFTR Protein Shields Heart Cells from Aging Beyond Its Ion Channel Role
Scientists reveal CFTR protein prevents cardiomyocyte senescence by reducing mitochondrial oxidative stress via a newly discovered deubiquitination pathway.
Summary
Researchers discovered that CFTR — a protein best known for its role in cystic fibrosis — also protects heart muscle cells from aging through a completely separate mechanism. In aging heart models, CFTR levels dropped significantly, while markers of cellular senescence rose. Restoring CFTR reduced oxidative stress damage and reactivated antioxidant defenses inside the cell's mitochondria. The protein works by boosting a calcium pump on the cell membrane, lowering internal calcium levels that would otherwise harm mitochondria. A companion protein called USP45 stabilizes CFTR by removing tags that mark it for degradation. Together, this USP45-CFTR partnership offers a potential new target for treating age-related heart disease.
Detailed Summary
Cardiovascular aging is one of the leading drivers of disease and death worldwide, yet the molecular switches that push heart muscle cells into irreversible senescence remain poorly understood. This study uncovers a surprising new role for CFTR — a protein previously studied almost exclusively as an ion channel mutated in cystic fibrosis — in protecting cardiomyocytes from age-related decline.
The researchers first examined human atrial tissue from patients with sinus rhythm versus atrial fibrillation of varying durations. CFTR expression was significantly lower in atrial fibrillation patients and inversely correlated with established senescence markers p16, p21, and p53, suggesting a clinically relevant link between CFTR loss and cardiac aging.
Using D-galactose-induced aging models in both live mice and isolated neonatal cardiomyocytes, the team showed that CFTR overexpression reduced key senescence markers and oxidative damage indicators including malondialdehyde, while restoring the activity of antioxidant enzymes superoxide dismutase, glutathione peroxidase, and catalase. Mechanistically, CFTR enhances plasma membrane calcium ATPase activity, lowering cytoplasmic calcium accumulation and thereby reducing mitochondrial oxidative stress — a non-channel function entirely separate from its classic ion transport role.
Critically, the study identified USP45 as a direct binding partner that stabilizes CFTR by removing K48-linked ubiquitin chains at the K688 residue, preventing its degradation. Overexpressing USP45 rescued cells in which CFTR had been knocked down, confirming the functional importance of this partnership.
For clinicians and longevity researchers, this reveals a novel therapeutic axis: targeting the USP45-CFTR-PMCA-mitochondria pathway could offer a highly specific intervention against cardiac senescence. Caveats include reliance on preclinical models and abstract-only access limiting full methodological evaluation.
Key Findings
- CFTR expression is reduced in atrial fibrillation patients and negatively correlates with senescence markers p16, p21, and p53.
- CFTR overexpression restores antioxidant enzyme activity and lowers oxidative damage in aging cardiomyocytes.
- CFTR reduces mitochondrial oxidative stress by boosting calcium pump activity, independent of its ion channel function.
- USP45 deubiquitinates CFTR at the K688 residue, preventing its degradation and sustaining its cardioprotective effects.
- USP45 overexpression rescues senescence even when CFTR is knocked down, validating the pathway as a therapeutic target.
Methodology
The study used human atrial tissue from sinus rhythm and atrial fibrillation patients to establish clinical relevance. D-galactose-induced senescence was modeled in both mice and neonatal mouse cardiomyocytes, with CFTR overexpression and knockdown experiments alongside USP45 manipulation to dissect the mechanistic pathway.
Study Limitations
This summary is based on the abstract only, as the full text was not accessible, which limits evaluation of statistical rigor and methodological detail. The study relies on preclinical models (mice and neonatal cardiomyocytes) and correlation data from human tissue, with no direct therapeutic intervention tested in humans. Translation of these findings to clinical practice will require validation in larger human cohorts and in vivo therapeutic trials.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: